Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Biopharm Stat ; 29(5): 800-809, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31454294

RESUMO

In traditional survival analyses, hazard ratio (HR) is commonly used to evaluate treatment effects. However, HR may not be easy to interpret. Restricted mean survival time is a viable alternative to HR, particularly when the proportional hazards assumption is not satisfied. We developed a conditional restricted mean survival time (CRMST) estimator for a time interval of interest using counting process. The variance of CRMST was estimated using a perturbation re-sampling method for asymptotic normality. The utility of our CRMST seems promising based on comprehensive simulation studies and a real data case study.


Assuntos
Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/mortalidade , Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos , Método Duplo-Cego , Seguimentos , Humanos , Inibidores da Agregação Plaquetária/uso terapêutico , Modelos de Riscos Proporcionais , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Processos Estocásticos , Taxa de Sobrevida/tendências
2.
Pulm Circ ; 3(1): 217-25, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23662200

RESUMO

In pulmonary hypertension, as in many other diseases, there is a need for a smarter approach to evaluating new treatments. The traditional randomized controlled trial has served medical science well, but constrains the development of treatments for rare diseases. A workshop was established to consider alternative clinical trial designs in pulmonary hypertension and here discusses their merits, limitations and challenges to implementation of novel approaches.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA